Baldwin Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
Baldwin Investment Management's VRTX Position: Q1 2026 in Review
Baldwin Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.69% in Q1 2026, buying an estimated $50.4K and bringing the position to 15,662 shares worth $6.99M. The position accounts for 0.82% of the portfolio, ranked #16.
Baldwin Investment Management first reported a position in VRTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $7.05M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Baldwin Investment Management held 15,662 shares of Vertex Pharmaceuticals worth $6.99M as of Q1 2026.
- Baldwin Investment Management bought 108 Vertex Pharmaceuticals shares in Q1 2026, an estimated $50.4K.
- Vertex Pharmaceuticals made up 0.82% of Baldwin Investment Management's portfolio in Q1 2026, its #16 holding.
- Baldwin Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
- Baldwin Investment Management's Vertex Pharmaceuticals position peaked at $7.05M in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Baldwin Investment Management's 13F filing for Q1 2026, filed 12 May 2026.